Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer
May 28th 2024The expert panel underscores the critical importance of rapid diagnostic testing and identification of driver alterations to optimize patient outcomes, given the often-narrow therapeutic window for chemotherapy and targeted therapies.
Read More
NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing
May 28th 2024Key opinion leaders examine the current National Comprehensive Cancer Network (NCCN) guidelines regarding the utilization of liquid and tissue biopsies, highlighting the necessity for the NCCN to prioritize and recommend concurrent testing as the preferred approach over relying on a single liquid or tissue biopsy alone.
Read More
Challenges and Unmet Needs in HER2-Mutated NSCLC
The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.
Read More
Adverse Events Associated With TKIs in HER2-Mutated NSCLC
D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.
Read More
Concurrent NSCLC Biomarker Testing at Diagnosis
May 21st 2024Martin Dietrich, MD, PhD, shares his approach to optimizing the use of diagnostic testing from both a tissue perspective and cost perspective, noting he routinely orders tissue and liquid biopsies during the initial patient visit if prior testing has not been conducted.
Read More
Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing
May 21st 2024Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the crucial role of molecular testing in disease diagnosis, focusing on the significance of rapid turnaround times and the ability of liquid biopsies to address time-sensitive diagnostic needs.
Read More
First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC
Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.
Read More
Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC
The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.
Read More
The Potential Role of TKIs in HER2-Mutated NSCLC
Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.
Read More
Managing Adverse Events Associated With ADCs in HER2-Mutated NSCLC
Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.
Read More
DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC
Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.
Read More
The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC
Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.
Read More
DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC
Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.
Read More
Role of ADCs in HER2-Mutated NSCLC
The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.
Read More
Biomarker Testing Challenges in HER2-mutated NSCLC
Experts on HER2-mutated non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.
Read More
A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2-mutated non–small cell lung cancer (NSCLC).
Read More
Future Perspectives on HER2 ADCs in Gynecological Cancer
February 8th 2024Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.
Read More
Expert Insights on HER2 Testing in Gynecological Cancers
February 8th 2024Ritu Salani, MD, provides expert insights regarding HER2 testing in patients with gynecological cancers, emphasizing the need for standardization in testing practices and greater clarity surrounding the incidence of HER2 positivity across gynecological cancers.
Read More
HER2 in Breast Cancer: Shaping Treatment in Other Solid Tumors
January 11th 2024Martin Dietrich, MD, PhD, reflects on the lessons and insights gleaned from HER2 in breast cancer, examining their influence on the development of treatment approaches utilizing HER2-targeted therapies in other solid tumors.
Read More
Advancement in Treating Uncommon EGFR Mutations: Key Takeaways
Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.
Read More
Investigational Avenues in Uncommon EGFR Mutations: NSCLC Treatment Insight
Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.
Read More
UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations
Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.
Read More
Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC
Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.
Read More